Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study.

Background: Limited and conflicting data have been reported on the impact of dupilumab (DUPI) on patch test (PT) results and its efficacy against allergic contact dermatitis (ACD).
Objective: This study was undertaken to analyze PT reactivities and relevance during treatment with DUPI to determine whether they could detect ACD in patients with uncontrolled or worsened atopic dermatitis (AD) who were receiving this agent.
Methods: This prospective, multicenter study examined 76 DUPI-treated patients who had undergone PTs. The relevant information was collected during 3 visits.
Results: Overall, 36 patients (47%) had ≥1 positive PT reaction, and 142 PT results were positive. Twenty-three patients (30%) had ≥1 positive and clinically relevant PT result. Five of them had clinical eczema improvement after allergen avoidance. We compared the PT results of 36 patients before and during DUPI therapy, representing 1230 paired PT allergens, of which 1022 were the same, 34 were positive, 44 were lost, and 130 were uninterpretable.
Limitations: Because the number of patients included remains limited, our findings should be confirmed with a larger sample.
Conclusion: Our results confirmed the usefulness of PTs for patients receiving DUPI, with good PT reproducibility. We suggest that all DUPI-treated patients with AD developing partial responses or experiencing symptom worsening should undergo PTs to look for contact sensitization.
Competing Interests: Conflicts of interest Author Soria has received honoraria for advisory boards from Sanofi and was a speaker at a meeting organized by Sanofi. Dr Raison-Peyron has received honoraria for personal fees from Sanofi. Dr Badaoui has received honoraria for conferences and for advisory boards from Sanofi. Dr Marcant was a speaker at a meeting organized by Sanofi. Dr Bara has received honoraria for expert for a round table by Sanofi. Dr Giordano-Labadie has received honoraria for advisory boards from Sanofi. Dr Amsler has received honoraria for conferences and was a speaker at a meeting organized by Sanofi. Dr Delaunay has received honoraria for advisory boards from Sanofi. Dr Pralong has received honoraria for advisory boards from Sanofi. Dr Boulard was a speaker at a meeting organized by Sanofi and has received honoraria for advisory boards, study from Sanofi. Dr Ferrier Le Bouedec has received honoraria for expert for a round table by Sanofi. Author Tauber has received honoraria from Sanofi. Dr Pasteur has received honoraria for advisory boards from Sanofi and speaker at scientific meetings by Sanofi. Dr Valois has received honoraria for advisory boards from Sanofi and was a speaker at a meeting organized by Sanofi. Dr Crépy reports being an investigator, a consultant, and a speaker for Sanofi. Dr Bernier has received honoraria for advisory boards from Sanofi.
(Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)